propranolol has been researched along with Movement Disorders in 20 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
Movement Disorders: Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Seven patients suffering from Parkinson's disease (PD) with severely disabling dyskinesia received low-dose propranolol as an adjunct to the currently used medical treatment." | 2.68 | Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease. ( Agid, Y; Bonnet, AM; Carpentier, AF; Vidailhet, M, 1996) |
| "Progress in the treatment of action myoclonus is especially noteworthy and has led to the implication of serotonin deficit in the pathophysiology of this syndrome." | 1.26 | New approaches in the management of hyperkinetic movement disorders. ( Fahn, S, 1977) |
| " In the antipsychotic classification, special attention is given to side effects (extrapyramidal motor signs, tardive dyskinesias, akathisis) and to dosage for the elderly." | 1.25 | Observations on the psychopharmacology of the aged. ( Eisdorfer, C, 1975) |
| " Although directly related to daily dosage of levodopa, the myoclonus was specifically blocked by the serotonin antagonist, methysergide." | 1.25 | Levodopa-induced myoclonus. ( Bergen, D; Goetz, C; Klawans, HL, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (50.00) | 18.7374 |
| 1990's | 5 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Horváth, K | 1 |
| Aschermann, Z | 1 |
| Komoly, S | 1 |
| Kovács, A | 1 |
| Kovács, N | 1 |
| Lerner, PP | 1 |
| Miodownik, C | 1 |
| Lerner, V | 1 |
| Yaman, A | 1 |
| Akdeniz, M | 1 |
| Yaman, H | 1 |
| Zappia, M | 1 |
| Albanese, A | 1 |
| Bruno, E | 1 |
| Colosimo, C | 1 |
| Filippini, G | 1 |
| Martinelli, P | 1 |
| Nicoletti, A | 1 |
| Quattrocchi, G | 1 |
| Abbruzzese, G | 1 |
| Berardelli, A | 1 |
| Allegra, R | 1 |
| Aniello, MS | 1 |
| Elia, AE | 1 |
| Martino, D | 1 |
| Murgia, D | 1 |
| Picillo, M | 1 |
| Squintani, G | 1 |
| Factor, SA | 1 |
| Strang, RR | 1 |
| Gerrard, JW | 1 |
| Richardson, JS | 1 |
| Donat, J | 1 |
| Carpentier, AF | 1 |
| Bonnet, AM | 1 |
| Vidailhet, M | 1 |
| Agid, Y | 1 |
| Rezayat, M | 1 |
| Azizi, N | 1 |
| Zarrindast, MR | 1 |
| Eisdorfer, C | 1 |
| Fahn, S | 1 |
| Klawans, HL | 1 |
| Goetz, C | 1 |
| Bergen, D | 1 |
| Barron, TF | 1 |
| Younkin, DP | 1 |
| Lou, JS | 1 |
| Jankovic, J | 1 |
| Krüger, K | 1 |
| Marsden, CD | 1 |
| Dill, RE | 1 |
| Jan, JE | 1 |
| Wilson, RA | 1 |
| Tzavellas, O | 1 |
| Metzel, E | 1 |
| Umbach, W | 1 |
| Kruse-Larsen, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Deep braIn Stimulation for Tremor TractographIC Versus Traditional[NCT02491554] | 24 participants (Anticipated) | Interventional | 2015-08-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for propranolol and Movement Disorders
| Article | Year |
|---|---|
[Treatment of tardive syndromes].
Topics: Amantadine; Antipsychotic Agents; Botulinum Toxins; Central Nervous System Agents; Cholinergic Antag | 2014 |
Tardive dyskinesia (syndrome): Current concept and modern approaches to its management.
Topics: Adrenergic beta-Antagonists; Adrenergic Uptake Inhibitors; alpha-Tocopherol; Amantadine; Anticonvuls | 2015 |
How best to address these common movement disorders.
Topics: Adrenergic beta-Antagonists; Adrenergic Uptake Inhibitors; Anticonvulsants; Antiparkinson Agents; Es | 2011 |
Treatment of essential tremor: a systematic review of evidence and recommendations from the Italian Movement Disorders Association.
Topics: Animals; Clinical Trials as Topic; Clozapine; Deep Brain Stimulation; Essential Tremor; Humans; Ital | 2013 |
2 trials available for propranolol and Movement Disorders
| Article | Year |
|---|---|
Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease.
Topics: Adrenergic beta-Antagonists; Adult; Antiparkinson Agents; Female; Humans; Levodopa; Male; Movement D | 1996 |
[Therapy of hypokinesia-akinesia in parkinsonism with beta-receptor-blocking agents. A clinical trial].
Topics: Adult; Aged; Cryosurgery; Female; Humans; Male; Middle Aged; Movement Disorders; Parkinson Disease; | 1969 |
14 other studies available for propranolol and Movement Disorders
| Article | Year |
|---|---|
Propranolol therapy for tardive dyskinesia revisited.
Topics: Adrenergic beta-Antagonists; Aged; Female; Humans; Male; Movement Disorders; Propranolol | 2012 |
The symptom of restless legs.
Topics: Adult; Aged; Anemia, Hypochromic; Chlordiazepoxide; Diazepam; Female; Humans; Iron; Leg; Male; Middl | 1967 |
Neuropharmacological evaluation of movement disorders that are adverse reactions to specific foods.
Topics: Adult; Animals; Aspartame; Carbidopa; Coffee; Diazepam; Double-Blind Method; Eggs; Female; Food Hype | 1994 |
On the mechanism(s) of cholecystokinin (CCK): receptor stimulation attenuates morphine dependence in mice.
Topics: Adrenergic Antagonists; Animals; Atropine; Benzazepines; Ceruletide; Dopamine Antagonists; Male; Met | 1997 |
Observations on the psychopharmacology of the aged.
Topics: Aged; Amantadine; Antidepressive Agents; Antipsychotic Agents; Basal Ganglia Diseases; Butyrophenone | 1975 |
New approaches in the management of hyperkinetic movement disorders.
Topics: 5-Hydroxytryptophan; Carbidopa; Chorea; Dyskinesia, Drug-Induced; Humans; Movement Disorders; Myoclo | 1977 |
Levodopa-induced myoclonus.
Topics: 5-Hydroxytryptophan; Aged; Amantadine; Amphetamine; Animals; Benztropine; Dopamine Antagonists; Dose | 1975 |
Propranolol therapy for shuddering attacks.
Topics: Activities of Daily Living; Child, Preschool; Consciousness; Female; Humans; Movement Disorders; Pro | 1992 |
Essential tremor: clinical correlates in 350 patients.
Topics: Adult; Aged; Aging; Alcohol Drinking; Female; Humans; Male; Middle Aged; Movement Disorders; Primido | 1991 |
[On the drug therapy of ergotropic sympathicotonic cardiovascular disorders].
Topics: Adult; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Cardiac Output; Cardiovascular Diseases; | 1967 |
Drug treatment of diseases characterized by abnormal movements.
Topics: Chorea; Diazepam; Ethanol; Haloperidol; Humans; Huntington Disease; Levodopa; Movement Disorders; My | 1973 |
Mescaline: receptor interaction in the rat striatum.
Topics: Animals; Basal Ganglia; Behavior, Animal; Caudate Nucleus; Chlorpromazine; Cyclic AMP; Dopamine; Dru | 1972 |
Unusual late neurological sequelae in galactosaemia.
Topics: Adult; Age Factors; Amantadine; Bender-Gestalt Test; Cerebellar Diseases; Diet Therapy; Erythrocytes | 1973 |
The clinical effect of catecholamine-blocking drugs (alpha-methyldopa, propanolol) in patients with hyperkinetic disorders.
Topics: Electroencephalography; Electromyography; Humans; Methyldopa; Movement Disorders; Propranolol | 1967 |